Teleflex (TFX)
(Delayed Data from NYSE)
$243.54 USD
+1.62 (0.67%)
Updated Aug 29, 2024 04:00 PM ET
After-Market: $243.62 +0.08 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value F Growth F Momentum D VGM
Brokerage Reports
0 items in cart
Teleflex Incorporated [TFX]
Reports for Purchase
Showing records 421 - 440 ( 478 total )
Company: Teleflex Incorporated
Industry: Medical - Instruments
Takeaways from SAGES; Minimally Invasive Pathways to Growth for TFX - CNMD
Provider: KEYBANC CAPITAL MARKETS
Company: Teleflex Incorporated
Industry: Medical - Instruments
Broader Recovery in CC Growth; Lower Gross Margin a Surprise
Provider: KEYBANC CAPITAL MARKETS
Company: Teleflex Incorporated
Industry: Medical - Instruments
Valuation Likely Already Captures Much of the NT Optimism Following VASC
Provider: KEYBANC CAPITAL MARKETS
Company: Teleflex Incorporated
Industry: Medical - Instruments
Post VASC Close, Confident in Its DD Growth Drivers and 2018 Accretion Targets
Provider: KEYBANC CAPITAL MARKETS
Company: Teleflex Incorporated
Industry: Medical - Instruments
Medical Technology: 4Q Preview; No Real Changes to Outlooks; Reducing Estimates Again for FX
Provider: KEYBANC CAPITAL MARKETS
Company: Teleflex Incorporated
Industry: Medical - Instruments
Larger - More Expensive, but Consistent with Strategy of Acquiring Sales Growth - Gross Margin Accretive Targets
Provider: KEYBANC CAPITAL MARKETS
Company: Teleflex Incorporated
Industry: Medical - Instruments
Research Summary
Provider: KEYBANC CAPITAL MARKETS
Company: Teleflex Incorporated
Industry: Medical - Instruments
Industry: Takeaways from AAGL
Provider: KEYBANC CAPITAL MARKETS
Company: Teleflex Incorporated
Industry: Medical - Instruments
Growth and Margin Expectations Appear More Muted NT; Lowering Estimates
Provider: KEYBANC CAPITAL MARKETS
Company: Teleflex Incorporated
Industry: Medical - Instruments
Reduced Sales Guidance and Changes to Restructuring Actions Likely to Offset EPS Positives
Provider: KEYBANC CAPITAL MARKETS
Company: Teleflex Incorporated
Industry: Medical - Instruments
Benefits of Gross Margin Initiatives Evident and Driving EPS Leverage
Provider: KEYBANC CAPITAL MARKETS
Company: Teleflex Incorporated
Industry: Medical - Instruments
Similar to Peers, Solid Quarter and Modest Bump to EPS Guidance
Provider: KEYBANC CAPITAL MARKETS
Company: Teleflex Incorporated
Industry: Medical - Instruments
Research Summary
Provider: KEYBANC CAPITAL MARKETS
Company: Teleflex Incorporated
Industry: Medical - Instruments
Morning Meeting Notes
Provider: KEYBANC CAPITAL MARKETS
Company: Teleflex Incorporated
Industry: Medical - Instruments
Valuation Still Matters; Downgrade to SW
Provider: KEYBANC CAPITAL MARKETS
Company: Teleflex Incorporated
Industry: Medical - Instruments
Raising Estimates and PT, but Still See Incremental Upside to our Model
Provider: KEYBANC CAPITAL MARKETS
Company: Teleflex Incorporated
Industry: Medical - Instruments
Results a Modest Positive, but Expectations Were Raised Given Competitive Reports
Provider: KEYBANC CAPITAL MARKETS
Company: Teleflex Incorporated
Industry: Medical - Instruments
Morning Meeting Notes
Provider: KEYBANC CAPITAL MARKETS
Company: Teleflex Incorporated
Industry: Medical - Instruments
Industry: Takeaways from SAGES Meetings; Incrementally Positive on TFX - HRC
Provider: KEYBANC CAPITAL MARKETS
Company: Teleflex Incorporated
Industry: Medical - Instruments
Organic Growth and Margin Trajectory Strengthening into 2016; Raise PT to $159
Provider: KEYBANC CAPITAL MARKETS